5kits zhao

Calendar

January 2011
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  

Pages

Archives

Blogroll






 

By Selena Chavis
Reviewed by John M. Grohol, Psy.D. on October 7, 2010

The U.S. Food and Drug Administration (FDA) has given the green light to the nonstimulant medication Kapvay (clonidine hydrochloride) as the first drug used to treat attention deficit hyperactivity disorder (ADHD) that can be used as an add-on therapy to stimulant medication.

Kapvay has been approved as an extended-release tablet and extended-release oral formula for treatment in children ages 6 to 17 years.

It’s currently the only formulation of clonidine hydrochloride approved by the FDA for the treatment of ADHD and can be used as a monotherapy as well.

Manufactured by Shionogi, Kapvay is a centrally acting alpha2-adrenergic receptor agonist. These receptors are believed to involve the prefrontal cortex (PFC) of the brain.

Studies suggest that the PFC regulates attention and plays a critical role in impulse control, working memory and executive function.

“The FDA approval of Kapvay represents an exciting milestone in the field of ADHD,” said Donald C. Manning, MD, PhD, chief medical officer of Shionogi.

“The extended-release formulation of Kapvay minimizes the peaks and troughs in blood levels, thereby decreasing overactivation of the alpha receptors in the brain and periphery.”

Read in Full:  http://psychcentral.com/news/2010/10/07/first-adhd-add-on-drug-approved/19278.html



Leave a Reply

*